Arterial hypertension and metabolic syndrome: specifics of antihypertensive therapy
https://doi.org/10.15829/1728-8800-2011-4-107-109
Abstract
This review summarizes the literature evidence on humoral disturbances in arterial hypertension (AH), as well as on AH interrelationship with individual components of metabolic syndrome (MS). Based on the results of multi-centre randomised trials, the rationale for the use of antihypertensive agents with favourable metabolic profile is demonstrated, in particular, for antagonists of slow calcium channels, angiotensin-converting enzyme inhibitors, and selective imidazoline receptor agonists.
About the Authors
L. I. Abasova
Research Institute of Cardiology
Azerbaijan
Baku
Azerbaijan
Baku
R. L. Dashdamirov
Research Institute of Cardiology
Azerbaijan
Baku
Azerbaijan
Baku
A. B. Bakhshaliev
Research Institute of Cardiology
Azerbaijan
Baku
Azerbaijan
Baku
References
1. Небиеридзе Д.В. Рилменидин — один из первых представителей агонистов имидазолиновых рецепторов: новые возможности лечения артериальной гипертензии. Артер гиперт 2002; 8 (4): 147-50.
2. Суслина З.А., Ионова В.Г., Танашян М.М. и др. Дисрегуляция гемореологии и гемостаза при артериальной гипертонии. Кардиоваск тер профил 2003; 4: 54-7.
3. Чазова И.Е., Мычка В.Б. Метаболический синдром. Москва 2004; 163 с.
4. Шевченко О.П., Праскурничий Е.А., Шевченко А.О. Метаболический синдром. Москва 2004; 141с.
5. Balazsi I, Takacs J. The effect of lisinopril on hypertensive patients suffering in diabetic nephropathy. Diabetologia Hungarica 1999;7(2): 101-6.
6. Bousquet P, Dontenwill M, Greney H, Feldman J. Imidazoline Receptors in Cardiovascular and Metabolic Diseases. J Cardiovasc Pharmacol 2000; 35 (suppl. 4): 21-5.
7. Brown Mi, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-action calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72.
8. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with metabolic syndrome. Diabetes Care 2001; 24: 683-9.
9. Julius S, Nesbitt S. Sympathetic Overactivity in Hypertension: a Moving Target. Am J Hypertens 1996; 9: 113-20.
10. Krentz AJ, Evans AJ. Selective Imidazoline Receptors Agonists for Metabolic Syndrome. Lancet 1998; 351: 152-4.
11. Litchell H. Metabolic effects of antihypertensive drugs interacting with sympathetic nervous system. Eur Heart J 1992; 13 (Suppl. A): 53-7.
12. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
13. Rabbia F, Martini G, Genova CG, et al. Antihypertensive drugs and sympathetic nervous system. Clin Exp Hyperens 2001; 23: 101-11.
14. Reid JL. Update on Rilmenidine: Clinical Benefits. Am J Hypertens 2001; 14: 322-4.
15. Reisin E. TROPHY study. Hypertens 1997; 30(1): 140-5.
16. Seccia TM, Vulpis V, Ricci S, et al. Antihypertensive and metabolic effect of amlodipine in patients with non-insulindependent diabetes mellitus. Clin Drue Invest 1995; 9 (1): 16-21.
17. Thakur V, Richards R, Reisin E. Obesity, hypertension, and the heart. Am J Med Sci 2001; 3.
18. Van Zwieten PA. The Renaissance of Centrally Acting Antihypertensive Drugs. J Hypertens 1999; 17(suppl. 3): 15-21.
Review
For citations:
Abasova L.I., Dashdamirov R.L., Bakhshaliev A.B. Arterial hypertension and metabolic syndrome: specifics of antihypertensive therapy. Cardiovascular Therapy and Prevention. 2011;10(4):107-109. (In Russ.) https://doi.org/10.15829/1728-8800-2011-4-107-109
Views:
2057
Email this article 
